Pocket Program - CROI

Tuesday
March 5 Oral Sessions
Session 32 CROI 2013
b Tuesday, 1:30-2:30 pm; Ballroom 1-2
Session 32–Themed Discussion
(see Session 130 on Monday for corresponding Poster Abstracts)
Cardiovascular Disease: Predicting Risk and
Monitoring Outcomes
Discussants:
John Brooks, CDC, Atlanta, GA, US
Monica Shah, Natl Heart, Lung, and Blood Inst, NIH, Bethesda, MD,US
747 Projecting 10-year, 20-year, and Lifetime Risks of
Cardiovascular Disease in HIV + Individuals in the
US: Competing Risks and Premature Aging
Elena Losina* 1,2,3,4 , B Linas4,5 , E Hyle1,3 , C Rusu4 , F Noubary4 ,
B Berkowitz4 , P Sax1,2 , M Weinstein6 , R Walensky1,2,3,4 , and K Freedberg1,3,4,5 1 2 Ctr for AIDS Res, Harvard Med Sch, Boston, MA, US;; Brigham and
Womens Hosp, Boston, MA, US;; 3Massachusetts Gen Hosp, Boston, US;;
4 5 Boston Med Ctr, MA, US;; Boston Univ Sch of Publ Hlth, MA, US;; and
6Harvard Sch of Publ Hlth, Boston, MA, US
748 Improvements in Short-term Mortality following
Myocardial Infarction: The Data Collection on
Adverse events of Anti-HIV Drugs Study
Caroline Sabin* 1 , L Ryom2 , M Law3 , W El-Sadr4 , O Kirk2,5 , M Bruyand6 ,
P Reiss7 , C Pradier8 , B Ledergerber9 , J Lundgren2,5 , and D:A:D Study
1 2 3 Univ Coll London, UK;; Copenhagen HIV Prgm, Denmark;; The Kirby
Inst, Univ of New South Wales, Sydney, Australia;; 4Intl Ctr for AIDS Care
and Treatment Prgms, Columbia Univ and Harlem Hosp, New York, NY,
US;; 5Copenhagen Univ Hosp/Rigshospitalet, Denmark;; 6Univ of Bordeaux,
ISPED, Ctr INSERM U897-Epidemiologie-Biostatistique, France;;
7 8 Academic Med Ctr, Univ of Amsterdam, The Netherlands;; Ctr Hosp Univ,
Nice, France;; and 9Univ Hosp Zurich, Switzerland
749 ST2 and NT-proBNP Are Associated with Cardiac
Dysfunction and Mortality in HIV + Individuals
Eric Secemsky* 1 , R Scherzer2 , E Nitta2 , A Wu2 , D Lange2 , S Deeks2 ,
J Martin2 , J Snider3 , P Ganz2 , and P Hsue2 1 2 Massachusetts Gen Hosp, Boston, US;; Univ of California, San Francisco,
US;; and 3Critical Diagnostics, San Diego, CA, US
750 The Risk of and Survival with Preserved vs Reduced
Ejection Fraction Heart Failure by HIV Status
Matthew Freiberg* 1 , C-C Chang1 , KA Oursler2,3 , J Gottdiener4 ,
S Gottlieb4 , A Warner5 , D Leaf5 , M Rodriguez-Barradas6,7 , S Felter8 ,
A Butt1,9 , and VACS Project Team
1 2 3 Univ of Pittsburgh Sch of Med, PA, US;; Baltimore VAMC, MD, US;; Univ
of Maryland Sch of Med, Baltimore, US;; 4Univ of Maryland Med Ctr,
Baltimore, US;; 5VA Greater Los Angeles Hlthcare System, CA, US;; 6Baylor Coll of Med, Houston, TX, US;; 7Michael E DeBakey VAMC, Houston, TX,
US;; 8VA Pittsburgh Hlthcare System, PA, US;; and 9Sheikh Khalifa Med
City, Abu Dhabi, United Arab Emirates
751 Emergency Medical Service Utilization and
Reperfusion Times among HIV + Individuals
Presenting with ST-elevation Myocardial Infarction
Mark Dela Cruz* 1 , K Thomas1 , D Brenner1 , A Kulkarni2 , J McCabe3 ,
P Hsue1 , P Ganz1 , and S Waldo1 1 2 Univ of California, San Francisco, US;; Massachusetts Gen Hosp, Boston,
US;; and 3Brigham and Womens Hosp, Boston, MA, US
14 20th Conference on Retroviruses and Opportunistic Infections
C Tuesday, 2:30-4 pm; Hall B2
Poster Abstracts
(see full session listings starting on page 24)
Session 56. Transcription/Reverse and Forward, Splicing/Replication
Session 60. Restriction Factors: APOBEC and Others
Session 62. Shutting the Door on HIV Entry
Session 63. Transmitted/Founder Viruses
Session 66. Markers of HIV Disease Progression
Session 69. CD8 T Cells in HIV Infection
Session 70. Killer T Cells
Session 78. Viral DNA Dynamics
Session 79. Infected Cell Dynamics on Therapy
Session 80. What Is Latency and What Can We Do about It?
Session 82. Novel Vaccine Strategies
Session 88. Neuropathogenesis Mechanisms
Session 89. Central Nervous System Inflammation and Biomarkers
of HIV-associated Neurocognitive Disorders
Session 90. Aging and Neurocognitive Function in HIV Infection
Session 94. Simian Viral Reservoirs
Session 97. HIV Subtypes: Epidemiology and Disease Progression
Session 99. New Approaches to ARV Drug Delivery
Session 102. ARV Pharmacokinetics: New Assays, Drugs, and
Special Populations
Session 110. Tropism Testing/Maraviroc Resistance
Session 111. HIV Drug Resistance: Trends and Emergence
Session 112. Detecting and Interpreting HIV Drug Resistance
Session 113. Innovation in Measuring Viral Nucleic Acids
Session 114. Transmitted Drug Resistance
Session 115. Drug Resistance Mutational Pathways and Subtype
Associations
Session 116. Advances in Sequencing and Analysis
Session 117. Detecting HIV Infection
Session 122. Hepatitis C Virus Treatment Today and Tomorrow
Session 123. Hepatitis C Virus Resistance and Virology
Session 124. Innate Immunity and Hepatitis C Virus
Session 126. Hepatic Failure and Transplantation
Session 127. Emergence and Persistence of HPV-associated
Malignancies in the ART Era
Session 133. Statin Use and HIV: How Sweet Is It?
Session 134. Dyslipidemia: Risks, Pathogenesis, and Treatment
Session 135. Risk Prediction, Risk Factors, Biomarkers, and
Outcomes
Session 137. Inflammatory Biomarkers, Microparticles, and Clinical
Outcomes in HIV
Session 138. ART Effects: Monocyte and T Cell Activation
Session 147. TB Screening Strategies: Diagnostics New and Old and
Latent TB Treatment
Session 149. Mechanisms of Immune Reconstitution
Session 157. Hepatitis C Virus Testing in Women
Session 163. ARV Strategies, MTCT, and HIV-free Survival
Session 164. PMTCT Implementation: Barriers and Program
Innovations
Session 167. Breast Feeding and Prevention of Postnatal MTCT
Session 168. ARV Pharmacokinetics during Pregnancy and Breast
Feeding
Session 169. ARV Regimens and Safety during Pregnancy
Session 175. HIV Drug Resistance in Children and Youth
Session 176. Co-infections among HIV-infected and -exposed Children
Session 184. Non-human Primate Models of STI, PrEP, and Vaccines
Session 186. Implementation and Cost-effectiveness of Male
Circumcision
Session 188. The Ongoing Epidemic in MSM
Session 193. Estimating Incidence
Session 194. New Testing Strategies
Session 198. Adherence and Retention in RLS